306 related articles for article (PubMed ID: 8889507)
21. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.
Matsuoka S; Thompson JS; Edwards MC; Bartletta JM; Grundy P; Kalikin LM; Harper JW; Elledge SJ; Feinberg AP
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3026-30. PubMed ID: 8610162
[TBL] [Abstract][Full Text] [Related]
22. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5.
Besnard-Guérin C; Newsham I; Winqvist R; Cavenee WK
Hum Genet; 1996 Feb; 97(2):163-70. PubMed ID: 8566947
[TBL] [Abstract][Full Text] [Related]
23. Molecular biology of Wilms' tumor.
Koo HP; Hensle TW
Urol Clin North Am; 1993 May; 20(2):323-31. PubMed ID: 8388135
[TBL] [Abstract][Full Text] [Related]
24. Loss of heterozygosity at chromosome regions 22q11-12 and 11p15.5 in renal rhabdoid tumors.
Schofield DE; Beckwith JB; Sklar J
Genes Chromosomes Cancer; 1996 Jan; 15(1):10-7. PubMed ID: 8824720
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
26. Biology of Wilms' tumour.
Pritchard-Jones K; Hawkins MM
Lancet; 1997 Mar; 349(9053):663-4. PubMed ID: 9078193
[No Abstract] [Full Text] [Related]
27. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
28. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
29. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
30. Isolation of kidney complementary DNAs down-expressed in Wilms' tumor by a subtractive hybridization approach.
Austruy E; Cohen-Salmon M; Antignac C; Béroud C; Henry I; Nguyen VC; Brugières L; Junien C; Jeanpierre C
Cancer Res; 1993 Jun; 53(12):2888-94. PubMed ID: 7916648
[TBL] [Abstract][Full Text] [Related]
31. Genetics of Wilms' tumor.
Coppes MJ; Egeler RM
Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.
Perotti D; De Vecchi G; Testi MA; Lualdi E; Modena P; Mondini P; Ravagnani F; Collini P; Di Renzo F; Spreafico F; Terenziani M; Sozzi G; Fossati-Bellani F; Radice P
Hum Mutat; 2004 Nov; 24(5):400-7. PubMed ID: 15459955
[TBL] [Abstract][Full Text] [Related]
33. Genomic imprinting of a human apoptosis gene homologue, TSSC3.
Lee MP; Feinberg AP
Cancer Res; 1998 Mar; 58(5):1052-6. PubMed ID: 9500470
[TBL] [Abstract][Full Text] [Related]
34. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
Haber DA; Buckler AJ
New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11.
Wadey RB; Pal N; Buckle B; Yeomans E; Pritchard J; Cowell JK
Oncogene; 1990 Jun; 5(6):901-7. PubMed ID: 2163053
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
37. Intragenic homozygous deletion of the WT1 gene in Wilms' tumor.
Tadokoro K; Fujii H; Ohshima A; Kakizawa Y; Shimizu K; Sakai A; Sumiyoshi K; Inoue T; Hayashi Y; Yamada M
Oncogene; 1992 Jun; 7(6):1215-21. PubMed ID: 1350671
[TBL] [Abstract][Full Text] [Related]
38. Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.
Baird P; Wadey R; Cowell J
Oncogene; 1991 Jul; 6(7):1147-9. PubMed ID: 1861864
[TBL] [Abstract][Full Text] [Related]
39. Paternally inherited submicroscopic duplication at 11p15.5 implicates insulin-like growth factor II in overgrowth and Wilms' tumorigenesis.
Algar EM; St Heaps L; Darmanian A; Dagar V; Prawitt D; Peters GB; Collins F
Cancer Res; 2007 Mar; 67(5):2360-5. PubMed ID: 17325026
[TBL] [Abstract][Full Text] [Related]
40. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
